CDK4 and cancer: In the frame of a serial testing for KRAS mutations in liquid biopsies in patients undergoing CDK4/6i, a rise in the circulating mutated ctDNA number of copies/mL might represent a potential marker of cancer cell resistance onset, might anticipate the clinical evidence of disease progression, and thus might allow a rational change in cancer therapy.